Boicean Adrian, Ichim Cristian, Sasu Sabina-Maria, Todor Samuel Bogdan
Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania.
J Clin Med. 2025 Apr 14;14(8):2678. doi: 10.3390/jcm14082678.
Over time, extensive research has underscored the pivotal role of gut microbiota in the onset and progression of various diseases, with a particular focus on fecal microbiota transplantation (FMT) as a potential therapeutic approach. The practice of transferring fecal matter from a healthy donor to a patient provides valuable insights into how alterations in gut microbiota can impact disease development and how rectifying dysbiosis may offer therapeutic benefits. Re-establishing a balanced symbiotic relationship in the gastrointestinal tract has shown positive results in managing both intestinal and systemic conditions. Currently, one of the most pressing global health issues is metabolic syndrome-a cluster of conditions that includes insulin resistance, lipid imbalances, central obesity and hypertension. In this context, FMT has emerged as a promising strategy for addressing key components of metabolic syndrome, such as improving insulin sensitivity, body weight and lipid profiles. However, further well-structured studies are needed to refine treatment protocols and establish the long-term safety and efficacy of this intervention.
随着时间的推移,大量研究强调了肠道微生物群在各种疾病的发生和发展中所起的关键作用,尤其关注粪便微生物群移植(FMT)作为一种潜在的治疗方法。将健康供体的粪便物质转移到患者体内的做法,为肠道微生物群的改变如何影响疾病发展以及纠正生态失调如何带来治疗益处提供了有价值的见解。在胃肠道中重新建立平衡的共生关系已在管理肠道和全身疾病方面显示出积极效果。目前,全球最紧迫的健康问题之一是代谢综合征,这是一组包括胰岛素抵抗、脂质失衡、中心性肥胖和高血压的病症。在此背景下,FMT已成为解决代谢综合征关键组成部分(如改善胰岛素敏感性、体重和脂质谱)的一种有前景的策略。然而,需要进一步精心设计的研究来完善治疗方案,并确定这种干预措施的长期安全性和有效性。